Indocyanine Green

Indocyanine green (ICG) is a near-infrared fluorescent dye used primarily for intraoperative visualization, ophthalmic angiography, and selected cardiovascular, hepatic, and diagnostic applications. After intravenous administration, it binds rapidly to plasma proteins and is cleared mainly by the liver, making its use particularly relevant to procedures requiring real-time assessment of blood flow, tissue perfusion, biliary anatomy, or retinal and choroidal circulation. Adoption is shaped by clinical evidence, regulatory status, imaging-system availability, reimbursement, hospital protocols, and the need for trained operating-room and diagnostic staff.

The field is moving from dye administration as a standalone diagnostic step toward integrated fluorescence-guided workflows. Surgeons increasingly use near-infrared imaging to support vascular mapping, tissue perfusion assessment, lymphatic visualization, and biliary identification, while ophthalmology continues to use ICG angiography where deeper choroidal or retinal vascular information is clinically useful. This shift raises the importance of compatible imaging platforms, standardized dosing and documentation, workflow integration, staff training, and evidence demonstrating that fluorescence guidance improves procedural decision-making without creating avoidable delays or safety risks.

Artificial intelligence can extend the value of ICG by assisting with image enhancement, vessel and perfusion segmentation, pattern recognition, quantitative fluorescence analysis, and comparison of serial examinations. Its practical impact depends on high-quality annotated datasets, consistent imaging protocols, transparent validation, and safeguards against artifacts caused by motion, variable timing, tissue depth, or differences among camera systems. Near-term implementation is most credible when AI supports clinicians rather than replacing them, with human review, audit trails, cybersecurity controls, and prospective clinical validation remaining essential.

North America combines advanced surgical and ophthalmic infrastructure with strong interest in image-guided care, although adoption remains influenced by reimbursement, hospital procurement, and evidence requirements. Europe benefits from established tertiary-care networks and coordinated clinical research, while regulatory and purchasing processes vary across countries. Asia-Pacific includes sophisticated systems in Japan, South Korea, Australia, and major Chinese and Indian centers alongside substantial differences in access and training. Latin America is supported by leading urban hospitals but faces equipment and reimbursement constraints. The Middle East shows concentrated investment in advanced hospitals, whereas Africa remains highly heterogeneous, with access strongest in referral centers and limited by diagnostic capacity, supply continuity, and specialist availability.

ASEAN markets present varied healthcare financing, regulatory maturity, and access to fluorescence imaging, making regional training and interoperable procurement approaches valuable. BRICS members span advanced academic centers and substantial access gaps, with local manufacturing, public-sector purchasing, and clinical education influencing availability. The European Union supports cross-border evidence generation and regulatory alignment, while national reimbursement and hospital procurement still affect implementation. G7 countries generally possess strong research, specialist, and imaging capabilities but continue to evaluate clinical utility and cost-effectiveness. GCC countries are developing high-acuity hospital capacity through centralized investment, while NATO members show diverse health systems but share opportunities for trauma, vascular, surgical, and ophthalmic applications where evidence supports use.

Australia and Canada emphasize evidence-based hospital adoption across geographically dispersed systems. Brazil and Mexico have important tertiary-care capabilities but encounter uneven access beyond major urban centers. China is expanding advanced surgical and diagnostic capacity, while India combines high-volume specialist centers with pronounced regional variation. Japan and South Korea have mature imaging and surgical ecosystems, and Russia’s access is shaped by domestic healthcare policy, procurement, and supply-chain conditions. France, Germany, Italy, and Spain operate within the European framework while retaining national differences in reimbursement, procurement, and clinical practice. The United Kingdom has strong academic and specialist capabilities, with implementation influenced by health-system evaluation. The United States remains a major environment for fluorescence-guided procedural development, subject to regulatory clearance, clinical evidence, hospital purchasing, and training requirements.

Industry leaders should prioritize well-designed clinical studies that connect ICG-guided visualization with meaningful procedural and patient outcomes rather than relying solely on image quality. They should build standardized protocols for patient selection, dosing, timing, contraindication screening, adverse-event reporting, image capture, and interpretation. Partnerships among dye developers, imaging-system providers, hospitals, clinicians, and regulators can improve interoperability and evidence quality. Commercial and clinical teams should tailor implementation to regional infrastructure, invest in training and service support, and establish supply-continuity plans. AI-enabled tools should be introduced through controlled validation, explainable outputs, human oversight, privacy protection, and post-deployment monitoring.

This executive summary uses a structured review of authoritative clinical, regulatory, and health-system evidence relevant to indocyanine green and near-infrared fluorescence applications. The assessment distinguishes established uses from emerging applications and considers safety, workflow requirements, imaging compatibility, reimbursement, training, and regional access conditions. Geographic comparisons integrate the specified regions, country groups, and countries without inferring commercial performance. Interpretations should be updated as regulatory decisions, clinical guidelines, comparative studies, technology standards, and implementation evidence evolve.

Indocyanine green remains a versatile tool for vascular, ophthalmic, surgical, and selected diagnostic visualization, with its greatest strategic potential arising when the dye, imaging platform, clinical protocol, and trained team function as one workflow. Adoption will be strongest where evidence demonstrates better decision support or patient management, procurement aligns with validated use cases, and safety and training are systematically managed. Artificial intelligence may improve interpretation and quantification, but responsible clinical oversight and prospective validation remain central to translating technical capability into dependable care.